Skip to main content
. 2020 Feb 12;34(2):183–196. doi: 10.1007/s40259-020-00406-1

Fig. 2.

Fig. 2

Mean (± SD) plasma rituximab concentration versus time profiles after infusion 1 (a) and 2 (b) (main PK population). PK population excluding ADA-positive are considered. ADA antidrug antibody, PK pharmacokinetic, MabThera RTX-EU, Rituxan RTX-US, SD standard deviation